---

Accutane, Meridia, Crestor, Bextra, and Serevent are next?

Accutane, Meridia, Crestor, Bextra, and Serevent are next? -- Posted by JOE on 11-18-04 13:08

November 18, 2004
F.D.A. Called 'Defenseless' Against Unsafe Drugs
By THE ASSOCIATED PRESS

WASHINGTON (AP) -- The American public is "virtually defenseless" if
another medication such as Vioxx proves to be unsafe after it is
approved for sale, a government drug safety reviewer told a
congressional committee Thursday.

"I would argue that the FDA as currently configured is incapable of
protecting America against another Vioxx," said David Graham, who
warned that the arthritis drug had been linked to an increased risk of
heart attack and stroke.

He told the Senate Finance Committee that there were at least five
other drugs on the market today that should be looked at seriously to
see whether they should remain there. He cited the acne drug Accutane,
the weight loss drug Meridia, the anti-cholesterol drug Crestor, the
pain reliever Bextra, and the asthma drug Serevent.

AstraZeneca Pharmaceuticals, maker of Crestor, said it was confident
that the drug was safe. "To date, the FDA has not given us any
indication of a major concern regarding Crestor," said spokeswoman
Emily Denney.

Tim Lindberg, a spokesman for Abbott Laboratories, said "science
continues to support the safe use of Meridia to treat obesity, the
leading health epidemic in the U.S."

Carolyn Glynn, spokeswoman for Roche Pharmaceuticals, maker of
Accutane, said that "it's important to point out that this drug is
reserved for a very very serious indication, that it does carry risks
and that its very important for physicians, patients, pharmacists to
monitor, to conform to all of the risk programs because this drug is
extremely beneficial as long as its used safely and appropriately."

GlaxoSmithKline, maker of Serevent, issued a statement saying that it
"stands firmly behind" the product, "which is safe and effective when
used appropriately and in accordance with labeling and treatment
guidelines."

Representatives of Pfizer, the manufacturer of Bextra, were not
immediately available for comment.

Another FDA official, Dr. Sandra Kweder, said that she did not agree
with Graham's assessment with the risk posed by the five drugs singled
out by Graham.

She said "there is no magic formula" to determine the drugs that pose
the most pressing safety concerns. She said there are thousands of
drugs on the market, each one carrying risks and benefits. "That is
clearly Dr. Graham's opinion" regarding the five drugs, she said,
denying that the FDA intimidates scientists whose opinions differ with
superiors.

She was asked whether her office, the Office of New Drugs, is an
impediment to enforcing concerns about drug safety. "You know, sir,
that is not the FDA I know.

Vioxx's maker, Merck & Co. pulled the drug from the market on Sept. 30
after a study indicated the popular painkiller doubled the risk of
heart attacks and stroke when taken for longer than 18 months.

Raymond V. Gilmartin, the company president, said in prepared
testimony that Merck acted within four days of learning about the
risk.

"Given the availability of alternative therapies and the questions
raised by the data withdrawing Vioxx was consistent with an ethic that
has driven Merck actions and decisions for more than 100 years," he
said.

Gilmartin also said the company was surprised by the cardiovascular
risk because it differed from past clinical trials. "My wife was a
user of Vioxx until the day we withdrew it from the marketplace," he
said.

The Food and Drug Administration has defended its actions regarding
Vioxx. In a statement issued late Wednesday, the agency cited its
"well-documented and long-standing commitment to openness and
transparency in its review of marketed drugs."

However, Sen. Charles Grassley, R-Iowa, who chaired the hearing,
suggested that an independent board of drug safety might be needed to
ensure the safety of medications after they're approved for the
market.

"Consumers should not have to second-guess the safety of what's in
their medicine cabinet," he said.

Graham told the committee that research indicated that Vioxx caused up
to 160,000 heart attacks and strokes.

"If we were talking about Florida or Pennsylvania, 1 percent of the
entire state population would have been affected," he said. "I'm sorry
to say Sen. Grassley, but 67 percent of the citizens of Des Moines
would be affected and, what's worse -- the entire population of every
other city in the state of Iowa."

Graham said his research helped to coax the FDA to withdraw a number
of drugs including Fen-phen, a weight loss drug, Lotronex, Baycol and
Rezulin. "During my career I have recommended the market withdrawal of
12 drugs," he said. "Only two of these remain on the market today."

At the same time, though, he questioned the agency's commitment to
removing unsafe drugs from the market, since it would call into
question their earlier approval.

Sen. Jeff Bingaman, D-New Mexico, said the problem was within the
FDA's own culture.

"The culture within the FDA, being one where the pharmaceutical
industry, which the FDA is supposed to regulate, is seen by the FDA as
its client instead," he said.

He called on President Bush to appoint a new head for the agency.
Lester Crawford has been acting commissioner of the agency.

In the FDA statement, Crawford said the FDA initiated and paid for
reviews of Vioxx and antidepressants after those drugs had hit the
market. "That is evidence the system is working," Crawford said.

Critics contend the agency ignored risks in both instances, then
intimidated its own reviewers when they pointed to safety concerns.

In October, the FDA ordered that all antidepressants carry warnings
that they "increase the risk of suicidal thinking and behavior" in
children who take them.

The FDA's statement disturbed lawyer Andy Birchfield, who is
evaluating thousands of potential cases against Merck on behalf of
injured patients.

"How can they see that type of problem and look back and say 'We did
everything right'?" Birchfield said. "When they're not willing to
recognize mistakes, we have no hope for them voluntarily taking
measures to correct the situation."

Crawford's statement did not mention Graham by name, but suggested
that the reviewer was a maverick who did not follow agency protocol.

Graham was lead author on a research project that studied the records
of almost 1.4 million Kaiser Permanente patients, including 40,405
treated with Pfizer's Celebrex and 26,748 treated with Vioxx. The
study found that high doses of Vioxx tripled risks of heart attacks
and sudden cardiac death.

Vioxx was responsible for an additional 27,785 deaths from heart
ailments from 1999 to 2003, Graham concluded.

He has told congressional investigators that superiors pressured him
to soften his conclusions.

Crawford said in his statement that the reviewer "voluntarily chose to
revise his conclusions, and he did so, in his own words, "without
compromising my deeply held convictions."'

^------

Re: Accutane, Meridia, Crestor, Bextra, and Serevent are next? -- Posted by TED KRAMER,M.D. on 11-19-04 13:19

JOE wrote in message news:...
> November 18, 2004
> F.D.A. Called 'Defenseless' Against Unsafe Drugs
> By THE ASSOCIATED PRESS
>
> WASHINGTON (AP) -- The American public is "virtually defenseless" if
> another medication such as Vioxx proves to be unsafe after it is
> approved for sale, a government drug safety reviewer told a
> congressional committee Thursday.
>
> "I would argue that the FDA as currently configured is incapable of
> protecting America against another Vioxx," said David Graham, who
> warned that the arthritis drug had been linked to an increased risk of
> heart attack and stroke.
>
> He told the Senate Finance Committee that there were at least five
> other drugs on the market today that should be looked at seriously to
> see whether they should remain there. He cited the acne drug Accutane,
> the weight loss drug Meridia, the anti-cholesterol drug Crestor, the
> pain reliever Bextra, and the asthma drug Serevent.
>
> AstraZeneca Pharmaceuticals, maker of Crestor, said it was confident
> that the drug was safe. "To date, the FDA has not given us any
> indication of a major concern regarding Crestor," said spokeswoman
> Emily Denney.
>
> Tim Lindberg, a spokesman for Abbott Laboratories, said "science
> continues to support the safe use of Meridia to treat obesity, the
> leading health epidemic in the U.S."
>
> Carolyn Glynn, spokeswoman for Roche Pharmaceuticals, maker of
> Accutane, said that "it's important to point out that this drug is
> reserved for a very very serious indication, that it does carry risks
> and that its very important for physicians, patients, pharmacists to
> monitor, to conform to all of the risk programs because this drug is
> extremely beneficial as long as its used safely and appropriately."
>
> GlaxoSmithKline, maker of Serevent, issued a statement saying that it
> "stands firmly behind" the product, "which is safe and effective when
> used appropriately and in accordance with labeling and treatment
> guidelines."
>
> Representatives of Pfizer, the manufacturer of Bextra, were not
> immediately available for comment.
>
> Another FDA official, Dr. Sandra Kweder, said that she did not agree
> with Graham's assessment with the risk posed by the five drugs singled
> out by Graham.
>
> She said "there is no magic formula" to determine the drugs that pose
> the most pressing safety concerns. She said there are thousands of
> drugs on the market, each one carrying risks and benefits. "That is
> clearly Dr. Graham's opinion" regarding the five drugs, she said,
> denying that the FDA intimidates scientists whose opinions differ with
> superiors.
>
> She was asked whether her office, the Office of New Drugs, is an
> impediment to enforcing concerns about drug safety. "You know, sir,
> that is not the FDA I know.
>
> Vioxx's maker, Merck & Co. pulled the drug from the market on Sept. 30
> after a study indicated the popular painkiller doubled the risk of
> heart attacks and stroke when taken for longer than 18 months.
>
> Raymond V. Gilmartin, the company president, said in prepared
> testimony that Merck acted within four days of learning about the
> risk.
>
> "Given the availability of alternative therapies and the questions
> raised by the data withdrawing Vioxx was consistent with an ethic that
> has driven Merck actions and decisions for more than 100 years," he
> said.
>
> Gilmartin also said the company was surprised by the cardiovascular
> risk because it differed from past clinical trials. "My wife was a
> user of Vioxx until the day we withdrew it from the marketplace," he
> said.
>
> The Food and Drug Administration has defended its actions regarding
> Vioxx. In a statement issued late Wednesday, the agency cited its
> "well-documented and long-standing commitment to openness and
> transparency in its review of marketed drugs."
>
> However, Sen. Charles Grassley, R-Iowa, who chaired the hearing,
> suggested that an independent board of drug safety might be needed to
> ensure the safety of medications after they're approved for the
> market.
>
> "Consumers should not have to second-guess the safety of what's in
> their medicine cabinet," he said.
>
> Graham told the committee that research indicated that Vioxx caused up
> to 160,000 heart attacks and strokes.
>
> "If we were talking about Florida or Pennsylvania, 1 percent of the
> entire state population would have been affected," he said. "I'm sorry
> to say Sen. Grassley, but 67 percent of the citizens of Des Moines
> would be affected and, what's worse -- the entire population of every
> other city in the state of Iowa."
>
> Graham said his research helped to coax the FDA to withdraw a number
> of drugs including Fen-phen, a weight loss drug, Lotronex, Baycol and
> Rezulin. "During my career I have recommended the market withdrawal of
> 12 drugs," he said. "Only two of these remain on the market today."
>
> At the same time, though, he questioned the agency's commitment to
> removing unsafe drugs from the market, since it would call into
> question their earlier approval.
>
> Sen. Jeff Bingaman, D-New Mexico, said the problem was within the
> FDA's own culture.
>
> "The culture within the FDA, being one where the pharmaceutical
> industry, which the FDA is supposed to regulate, is seen by the FDA as
> its client instead," he said.
>
> He called on President Bush to appoint a new head for the agency.
> Lester Crawford has been acting commissioner of the agency.
>
> In the FDA statement, Crawford said the FDA initiated and paid for
> reviews of Vioxx and antidepressants after those drugs had hit the
> market. "That is evidence the system is working," Crawford said.
>
> Critics contend the agency ignored risks in both instances, then
> intimidated its own reviewers when they pointed to safety concerns.
>
> In October, the FDA ordered that all antidepressants carry warnings
> that they "increase the risk of suicidal thinking and behavior" in
> children who take them.
>
> The FDA's statement disturbed lawyer Andy Birchfield, who is
> evaluating thousands of potential cases against Merck on behalf of
> injured patients.
>
> "How can they see that type of problem and look back and say 'We did
> everything right'?" Birchfield said. "When they're not willing to
> recognize mistakes, we have no hope for them voluntarily taking
> measures to correct the situation."
>
> Crawford's statement did not mention Graham by name, but suggested
> that the reviewer was a maverick who did not follow agency protocol.
>
> Graham was lead author on a research project that studied the records
> of almost 1.4 million Kaiser Permanente patients, including 40,405
> treated with Pfizer's Celebrex and 26,748 treated with Vioxx. The
> study found that high doses of Vioxx tripled risks of heart attacks
> and sudden cardiac death.
>
> Vioxx was responsible for an additional 27,785 deaths from heart

> ailments from 1999 to 2003, Graham concluded.
>
> He has told congressional investigators that superiors pressured him
> to soften his conclusions.
>
> Crawford said in his statement that the reviewer "voluntarily chose to
> revise his conclusions, and he did so, in his own words, "without
> compromising my deeply held conviction
Crescor hurt me badly, I ruptured the long head of my biceps shortly
after starting Crescor. These drugs have powerful dangerous
side-effects. One should beware! Ted Kramer,M.D.

Re: Accutane, Meridia, Crestor, Bextra, and Serevent are next? -- Posted by Bill on 11-19-04 15:13

"TED KRAMER,M.D." wrote in message
news:afcc8f85.0411191319.7c5a1247@posting.google.com...
> Crescor hurt me badly, I ruptured the long head of my biceps shortly
> after starting Crescor. These drugs have powerful dangerous
> side-effects. One should beware! Ted Kramer,M.D.

Crestor has some risks too.

Bill

Did you have a question? -- Posted by computernewby on 11-23-04 10:19

This looks like a statement to me with absolutely no effort put forth is
this post besides a cut and paste of somebody else's article. Was there a
purpose in posting this here..probably not dickhead.

"JOE" wrote in message
news:no3qp0lodckmv6khls4ud8bon0m7q4gsj2@4ax.com...
> November 18, 2004
> F.D.A. Called 'Defenseless' Against Unsafe Drugs
> By THE ASSOCIATED PRESS
>
> WASHINGTON (AP) -- The American public is "virtually defenseless" if
> another medication such as Vioxx proves to be unsafe after it is
> approved for sale, a government drug safety reviewer told a
> congressional committee Thursday.
>
> "I would argue that the FDA as currently configured is incapable of
> protecting America against another Vioxx," said David Graham, who
> warned that the arthritis drug had been linked to an increased risk of
> heart attack and stroke.
>
> He told the Senate Finance Committee that there were at least five
> other drugs on the market today that should be looked at seriously to
> see whether they should remain there. He cited the acne drug Accutane,
> the weight loss drug Meridia, the anti-cholesterol drug Crestor, the
> pain reliever Bextra, and the asthma drug Serevent.
>
> AstraZeneca Pharmaceuticals, maker of Crestor, said it was confident
> that the drug was safe. "To date, the FDA has not given us any
> indication of a major concern regarding Crestor," said spokeswoman
> Emily Denney.
>
> Tim Lindberg, a spokesman for Abbott Laboratories, said "science
> continues to support the safe use of Meridia to treat obesity, the
> leading health epidemic in the U.S."
>
> Carolyn Glynn, spokeswoman for Roche Pharmaceuticals, maker of
> Accutane, said that "it's important to point out that this drug is
> reserved for a very very serious indication, that it does carry risks
> and that its very important for physicians, patients, pharmacists to
> monitor, to conform to all of the risk programs because this drug is
> extremely beneficial as long as its used safely and appropriately."
>
> GlaxoSmithKline, maker of Serevent, issued a statement saying that it
> "stands firmly behind" the product, "which is safe and effective when
> used appropriately and in accordance with labeling and treatment
> guidelines."
>
> Representatives of Pfizer, the manufacturer of Bextra, were not
> immediately available for comment.
>
> Another FDA official, Dr. Sandra Kweder, said that she did not agree
> with Graham's assessment with the risk posed by the five drugs singled
> out by Graham.
>
> She said "there is no magic formula" to determine the drugs that pose
> the most pressing safety concerns. She said there are thousands of
> drugs on the market, each one carrying risks and benefits. "That is
> clearly Dr. Graham's opinion" regarding the five drugs, she said,
> denying that the FDA intimidates scientists whose opinions differ with
> superiors.
>
> She was asked whether her office, the Office of New Drugs, is an
> impediment to enforcing concerns about drug safety. "You know, sir,
> that is not the FDA I know.
>
> Vioxx's maker, Merck & Co. pulled the drug from the market on Sept. 30
> after a study indicated the popular painkiller doubled the risk of
> heart attacks and stroke when taken for longer than 18 months.
>
> Raymond V. Gilmartin, the company president, said in prepared
> testimony that Merck acted within four days of learning about the
> risk.
>
> "Given the availability of alternative therapies and the questions
> raised by the data withdrawing Vioxx was consistent with an ethic that
> has driven Merck actions and decisions for more than 100 years," he
> said.
>
> Gilmartin also said the company was surprised by the cardiovascular
> risk because it differed from past clinical trials. "My wife was a
> user of Vioxx until the day we withdrew it from the marketplace," he
> said.
>
> The Food and Drug Administration has defended its actions regarding
> Vioxx. In a statement issued late Wednesday, the agency cited its
> "well-documented and long-standing commitment to openness and
> transparency in its review of marketed drugs."
>
> However, Sen. Charles Grassley, R-Iowa, who chaired the hearing,
> suggested that an independent board of drug safety might be needed to
> ensure the safety of medications after they're approved for the
> market.
>
> "Consumers should not have to second-guess the safety of what's in
> their medicine cabinet," he said.
>
> Graham told the committee that research indicated that Vioxx caused up
> to 160,000 heart attacks and strokes.
>
> "If we were talking about Florida or Pennsylvania, 1 percent of the
> entire state population would have been affected," he said. "I'm sorry
> to say Sen. Grassley, but 67 percent of the citizens of Des Moines
> would be affected and, what's worse -- the entire population of every
> other city in the state of Iowa."
>
> Graham said his research helped to coax the FDA to withdraw a number
> of drugs including Fen-phen, a weight loss drug, Lotronex, Baycol and
> Rezulin. "During my career I have recommended the market withdrawal of
> 12 drugs," he said. "Only two of these remain on the market today."
>
> At the same time, though, he questioned the agency's commitment to
> removing unsafe drugs from the market, since it would call into
> question their earlier approval.
>
> Sen. Jeff Bingaman, D-New Mexico, said the problem was within the
> FDA's own culture.
>
> "The culture within the FDA, being one where the pharmaceutical
> industry, which the FDA is supposed to regulate, is seen by the FDA as
> its client instead," he said.
>
> He called on President Bush to appoint a new head for the agency.
> Lester Crawford has been acting commissioner of the agency.
>
> In the FDA statement, Crawford said the FDA initiated and paid for
> reviews of Vioxx and antidepressants after those drugs had hit the
> market. "That is evidence the system is working," Crawford said.
>
> Critics contend the agency ignored risks in both instances, then
> intimidated its own reviewers when they pointed to safety concerns.
>
> In October, the FDA ordered that all antidepressants carry warnings
> that they "increase the risk of suicidal thinking and behavior" in
> children who take them.
>
> The FDA's statement disturbed lawyer Andy Birchfield, who is
> evaluating thousands of potential cases against Merck on behalf of
> injured patients.
>
> "How can they see that type of problem and look back and say 'We did
> everything right'?" Birchfield said. "When they're not willing to
> recognize mistakes, we have no hope for them voluntarily taking
> measures to correct the situation."
>
> Crawford's statement did not mention Graham by name, but suggested
> that the reviewer was a maverick who did not follow agency protocol.
>
> Graham was lead author on a research project that studied the records
> of almost 1.4 million Kaiser Permanente patients, including 40,405
> treated with Pfizer's Celebrex and 26,748 treated with Vioxx. The
> study found that high doses of Vioxx tripled risks of heart attacks
> and sudden cardiac death.
>
> Vioxx was responsible for an additional 27,785 deaths from heart
> ailments from 1999 to 2003, Graham concluded.
>
> He has told congressional investigators that superiors pressured him
> to soften his conclusions.
>
> Crawford said in his statement that the reviewer "voluntarily chose to
> revise his conclusions, and he did so, in his own words, "without
> compromising my deeply held convictions."'
>
> ^------
>

Related Discussion:

HIP NY worst Rx (prescription) plan (1 posts)
by MR - Last post on: 08-18-04 17:42
Three years of dealing with this plan has driven me nuts. Every time I take a prescription to a pharmacist I'm told HIP doesn't cover it. EVERY TIME! Then a process must start. It involves all of these parties being called at least twice: The doctor's receptionist, the doctor, HIP's toll fr... (Read More)

Neuropathy Help (1 posts)
by Doug - Last post on: 07-02-03 15:34
A study just published May 5, 2003 in the Archives of Physical Medicine reports that the constant wearing of static, permanent, magnetic insoles produces statistically significant reduction of neuropathic pain. When the Weintraub study was published, all three networks, ABC, NBC and CBS reported... (Read More)

Arthritis, Fibro, Etc.... (2 posts)
by familyzoo - Last post on: 10-02-04 04:49
I want offer an invitation to my website....It is a FREE website, that I built myself and take care of myself, to help others with chronic conditions find information, links, and more. I myself have MANY conditions including arthritis, fibro, cad, thyroid, etc. etc........Please DO NOT email me... (Read More)

Pfizer Suspends Celebrex Ads - U.S. FDA (1 posts)
by Roman Bystrianyk - Last post on: 12-20-04 05:12
http://www.healthsentinel.com/news.php?event=news_print_list_item&id=485 "Pfizer Suspends Celebrex Ads - U.S. FDA", Reuters UK, December 20, 2004, Link: http://www.reuters.co.uk/newsArticle.jhtml;jsessionid=3IGRHORR5EZJGCRBAEKSFFA?type=healthNews&storyID=7134595 Pfizer Inc. has agreed to su... (Read More)

Top Discussions From Our Archives

Health Benefits

Re: alt.support.scleroderma is up

Amazing results

Other Discussion Categories

Diabetes Symptoms

Home | Discussion Archives |